<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004660</url>
  </required_header>
  <id_info>
    <org_study_id>199/11860</org_study_id>
    <secondary_id>MAYOC-1889200</secondary_id>
    <secondary_id>R01DK042822</secondary_id>
    <nct_id>NCT00004660</nct_id>
  </id_info>
  <brief_title>Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy</brief_title>
  <official_title>Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the effects of 20 Gy of external-beam radiotherapy to 1 orbit vs. the
      untreated orbit at 3 and 6 months after therapy in patients with Graves' ophthalmopathy.

      II. Evaluate whether 20 Gy of external-beam radiotherapy delivered to the second orbit 6
      months later in the course of the disease produces effects of equal magnitude to those
      observed when the first orbit was treated.

      III. Relate the magnitude of treatment effects to the time since onset of eye symptoms.

      IV. Evaluate whether characteristics of radiation retinopathy are present 3 years after
      orbital radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: The posterior region of 1 orbit is irradiated over 2 weeks with
      supervoltage equipment. The other orbit is treated 6 months later. The sequence of therapy is
      randomly assigned.

      The untreated eye receives a simultaneous sham treatment during each radiotherapy session.

      Patients are followed at 3, 6, 9, 12, and 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1993</start_date>
  <completion_date type="Actual">January 1998</completion_date>
  <primary_completion_date type="Actual">January 1998</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Orbital Volume</measure>
    <time_frame>1 year</time_frame>
    <description>Orbital fat and muscle volumes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Graves' Disease</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Sham treatment</intervention_name>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Firm diagnosis of Graves' disease with normal thyroid function,
        i.e.: Thyroid-stimulating immunoglobulin positive Thyroxine 5-12.5 micrograms/dL
        Tri-iodothyronine 80-180 nanograms/dL Thyroid-stimulating hormone 0.2-8 milli-International
        unit (mIU/L) Euthyroid due to therapy acceptable Ophthalmopathy meeting at least 3 of the
        following criteria: Chemosis or lid edema Lid lag, lid retraction, or restrictive
        lagophthalmos Proptosis at least 20 mm by Krahn exophthalmometry in at least 1 eye Less
        than 4 mm discrepancy between eyes Patient perception of &quot;stare&quot; or &quot;bulge&quot; Extraocular
        muscle motion restriction in 1 or both eyes on clinical exam or by patient report of
        diplopia at extremes of gaze Extraocular muscle enlargement on computerized tomography
        (previous study results acceptable) Mild to moderate ophthalmopathy, i.e.: Orbital pain
        Lacrimation Photophobia Visual blurring or diplopia No optic neuropathy, i.e.: Afferent
        pupillary defect Impaired color vision on D-15 testing (unless congenital color perception
        deficiency) Visual field defect Impaired visual acuity No corneal ulcers --Prior/Concurrent
        Therapy-- No prior external-beam radiotherapy to the head and neck At least 2 weeks since
        corticosteroids --Patient Characteristics-- No prior head and neck tumors No diabetes No
        pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colum A. Gorman</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001 Sep;108(9):1523-34. Erratum in: Ophthalmology. 2004 Jul;111(7):1306.</citation>
    <PMID>11535445</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graves' disease</keyword>
  <keyword>thyroid disease</keyword>
  <keyword>endocrine disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

